Embedded Files
According to DelveInsight's evaluation, the worldwide Pulmonary Fibrosis development landscape includes over 110 major pharmaceutical organizations actively pursuing more than 140 therapeutic candidates, encompassing Clinical Trial evaluations, Treatment approaches, Mechanisms of Action, Administration Routes, and Pipeline Advancements.
DelveInsight's "Pulmonary Fibrosis Pipeline Insight, 2025" delivers extensive perspectives on the current clinical research landscape and expansion potential within the Pulmonary Fibrosis therapeutic arena.
This Pulmonary Fibrosis Pipeline analysis encompasses thorough commercial and clinical evaluations of investigational products spanning from preclinical stages through commercialization. The document features comprehensive drug descriptions, encompassing mechanisms of action, clinical research programs, regulatory submissions (where applicable), and developmental activities including technological innovations, partnerships, mergers and acquisitions, financial backing, regulatory designations, and additional product-specific information.
Key Highlights from the Pulmonary Fibrosis Pipeline Analysis:
Pharmaceutical organizations worldwide are dedicating substantial efforts toward innovative Pulmonary Fibrosis therapeutic development with notable achievements in recent years.
Organizations advancing Pulmonary Fibrosis treatments include Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeutics, Inc., GlaxoSmithKline, Amgen, Bristol-Myers Squibb, Endeavor Biomedicines, Syndax Pharmaceuticals, Regend Therapeutics, among others.
Investigational Pulmonary Fibrosis treatments across various clinical development stages include BI 1015550, OFEV (Nintedanib), Pirfenidone, SC1011, TTI-101, PLN-74809, GSK3915393, HZN-825, BMS-986278, taladegib, BI 181947, Axatilimab, REGEND001, and additional candidates anticipated to substantially influence the Pulmonary Fibrosis marketplace in upcoming years.
During November 2025, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-phase biotechnology firm specializing in treatments for unaddressed needs across CNS, inflammatory, and cardiometabolic conditions, revealed that the European Patent Office (EPO) approved European Patent 3749324. This intellectual property protects brilaroxazine's application in treating pulmonary fibrosis, encompassing idiopathic pulmonary fibrosis (IPF). The patent expansion reinforces the compound's worldwide protection framework, complementing existing coverage in the United States, China, and Japan. Furthermore, brilaroxazine received Orphan Drug Designation from the U.S. FDA for IPF treatment.
During September 2025, PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a biotherapeutics organization dedicated to transforming innovative research into meaningful therapies, presented updated findings from the open-label extension (OLE) of its Phase 2b ELEVATE IPF study examining deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis (IPF). Findings demonstrated that subjects previously administered placebo or pirfenidone during the 26-week randomized segment who subsequently switched to deupirfenidone for an additional 26 weeks in the OLE exhibited stabilized respiratory function. Featured as a late-breaking oral presentation at the 2025 European Respiratory Society (ERS) Congress in Amsterdam, these results highlight deupirfenidone's promise as a potential standard of care in IPF management.
During September 2025, United Therapeutics pursued regulatory authorization for Tyvaso (treprostinil) in idiopathic pulmonary fibrosis (IPF) based on favorable Phase III trial outcomes. In the TETON-2 investigation (NCT05255991), the inhaled prostacyclin analog demonstrated significant forced vital capacity (FVC) improvement, revealing a 95.6 mL elevation from baseline measurements. Given that FVC represents a critical marker of respiratory limitation in IPF, this finding carries substantial importance. Moreover, the systemic vasodilator extended the time to initial clinical deterioration event, satisfying its principal secondary objective.
During May 2025, Endeavor BioMedicines, a clinical-phase biotechnology company creating treatments for severe medical conditions, unveiled a post hoc evaluation from its completed Phase 2a investigation of the experimental compound ENV-101 (taladegib). The data suggested that idiopathic pulmonary fibrosis (IPF) patients receiving ENV-101 for 12 weeks demonstrated substantial reductions in pulmonary vessel volume, significant lung volume increases, and trends toward diminished lung fibrosis versus placebo. This evaluation, employing Qureight's sophisticated deep learning CT platform, was showcased in a poster display at the ATS 2025 International Conference.
During February 2025, Pliant Therapeutics, Inc. (Nasdaq: PLRX) temporarily suspended enrollment and treatment administration in the active BEACON-IPF Phase 2b study of bexotegrast for idiopathic pulmonary fibrosis (IPF) following a prespecified data assessment and guidance from the independent Data Safety Monitoring Board (DSMB). Nevertheless, previously enrolled participants will maintain trial involvement.
During January 2025, Mediar Therapeutics established a worldwide licensing partnership with Eli Lilly and Company to advance MTX-463 into Phase II clinical testing for idiopathic pulmonary fibrosis (IPF). MTX-463 represents a novel human IgG1 antibody engineered to block WISP1-driven fibrotic pathways linked to multiple serious diseases.
During December 2024, Boston-headquartered clinical-stage biotherapeutics organization PureTech declared that its Phase IIb investigation of deupirfenidone successfully achieved all primary and secondary objectives, showing reduced lung function deterioration in idiopathic pulmonary fibrosis (IPF) patients. The dose-optimization study evaluated deupirfenidone (LYT-100) over 26 days, indicating that the elevated dose effectively decelerated lung degradation. PureTech seeks to establish the therapy as a novel standard of care (SOC) for IPF.
Pulmonary Fibrosis Disease Overview
Pulmonary fibrosis represents a chronic respiratory condition characterized by thickening, stiffening, and scarring of lung tissue. This scarring impairs normal lung function, diminishing oxygen delivery capacity into the circulatory system. Progressively, individuals with pulmonary fibrosis may develop manifestations including persistent nonproductive cough, breathlessness (particularly during exertion), exhaustion, and diminished exercise capacity. The disorder can advance progressively and may arise from diverse causes, including environmental factors, autoimmune conditions, infections, specific medications, or may develop without identifiable cause (idiopathic pulmonary fibrosis).
Get a Free Sample PDF Report to know more about Pulmonary Fibrosis Pipeline Therapeutic Assessment-
Emerging Pulmonary Fibrosis Compounds Across Various Clinical Development Phases Include:
BI 1015550: Boehringer Ingelheim
OFEV (Nintedanib): Boehringer Ingelheim Pharma GmbH
Pirfenidone: PureTech
SC1011: Guangzhou JOYO Pharma
TTI-101: Tvardi Therapeutics
PLN-74809: Pliant Therapeutics, Inc.
GSK3915393: GlaxoSmithKline
HZN-825: Amgen
BMS-986278: Bristol-Myers Squibb
taladegib: Endeavor Biomedicines
BI 1819479: Boehringer Ingelheim
Axatilimab: Syndax Pharmaceuticals
REGEND001: Regend Therapeutics
Pulmonary Fibrosis Administration Routes
The Pulmonary Fibrosis pipeline analysis presents therapeutic evaluation of developmental drugs by Administration Route. Products are classified under various routes including:
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Pulmonary Fibrosis Molecular Classifications
Pulmonary Fibrosis Products are organized under different Molecular types including:
Monoclonal
Antibody Peptides
Polymer
Small molecule
Gene therapy
Pulmonary Fibrosis Pipeline Therapeutic Evaluation
Pulmonary Fibrosis Classification by Product Category
Pulmonary Fibrosis By Development Phase and Product Category
Pulmonary Fibrosis Classification by Administration Route
Pulmonary Fibrosis By Development Phase and Administration Route
Pulmonary Fibrosis Classification by Molecular Type
Pulmonary Fibrosis by Development Phase and Molecular Type
DelveInsight's Pulmonary Fibrosis Report encompasses approximately 140+ products across different clinical development phases including:
Late-phase products (Phase III)
Mid-phase products (Phase II)
Early-phase product (Phase I)
Preclinical and Discovery phase candidates
Discontinued & Inactive candidates
Administration Routes
Further Pulmonary Fibrosis product details are provided in the report. Download the Pulmonary Fibrosis pipeline report to learn more about the emerging Pulmonary Fibrosis therapies-
Notable Organizations in the Pulmonary Fibrosis Therapeutics Arena include:
Leading companies creating therapies for Pulmonary Fibrosis include United Therapeutics, Bellerophon Therapeutics, and MediciNova, among others.
Pulmonary Fibrosis Pipeline Evaluation:
The Pulmonary Fibrosis pipeline document delivers insights into:
Comprehensive information about organizations creating therapies for Pulmonary Fibrosis treatment with combined therapeutic candidates developed by individual companies.
Assessment of various therapeutic candidates organized into early-phase, mid-phase, and late-phase development for Pulmonary Fibrosis Treatment.
Pulmonary Fibrosis leading companies engaged in targeted therapeutic development with corresponding active and inactive (dormant or discontinued) initiatives.
Pulmonary Fibrosis Drugs under investigation based on developmental phase, administration route, target receptor, monotherapy or combination therapy, various mechanisms of action, and molecular classifications.
Comprehensive evaluation of partnerships (company-company collaborations and company-academia partnerships), licensing arrangements and financial details for future progression of the Pulmonary Fibrosis marketplace.
The document is constructed utilizing data and intelligence gathered from the researcher's proprietary databases, company/university platforms, clinical trial registries, conferences, SEC documents, investor materials, and highlighted press announcements from company/university platforms and industry-focused third-party resources.
Download Sample PDF Report to know more about Pulmonary Fibrosis drugs and therapies-
Pulmonary Fibrosis Pipeline Market Growth Factors
Increasing prevalence of IPF globally, especially in elderly populations, stimulating demand for novel therapies.
Progress in diagnostic technologies enabling earlier and more precise disease identification.
Robust research and development funding by pharmaceutical organizations targeting innovative antifibrotic and immunomodulatory pathways.
Regulatory assistance for orphan drugs, expediting authorizations and encouraging innovation.
Pulmonary Fibrosis Pipeline Market Challenges
Ambiguous disease origins and complicated pathophysiology create drug development obstacles.
Elevated failure rates in clinical investigations due to insufficient efficacy or safety concerns.
Costly development expenses for orphan disease therapies, impacting smaller biotechnology entities.
Restricted patient populations complicate recruitment for large-scale investigations.
Adverse effects of current antifibrotic drugs compromise patient compliance.
Regulatory obstacles in demonstrating long-term efficacy and safety of emerging therapies.
Scope of Pulmonary Fibrosis Pipeline Drug Analysis
Geographic Coverage: Global
Key Pulmonary Fibrosis Organizations: Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeutics, Inc., GlaxoSmithKline, Amgen, Bristol-Myers Squibb, Endeavor Biomedicines, Syndax Pharmaceuticals, Regend Therapeutics, and others
Key Pulmonary Fibrosis Treatments: BI 1015550, OFEV (Nintedanib), Pirfenidone, SC1011, TTI-101, PLN-74809, GSK3915393, HZN-825, BMS-986278, taladegib, BI 181947, Axatilimab, REGEND001, and others
Pulmonary Fibrosis Therapeutic Classification: Pulmonary Fibrosis currently marketed and Pulmonary Fibrosis emerging treatments
Pulmonary Fibrosis Market Forces: Pulmonary Fibrosis market growth factors and Pulmonary Fibrosis market challenges
About DelveInsight
DelveInsight represents a premier Business Consultant and Market Research organization concentrated exclusively on life sciences. It supports Pharmaceutical companies by delivering comprehensive end-to-end solutions to enhance their performance. It additionally provides Healthcare Consulting Services, which contribute to market evaluation to accelerate business expansion and address challenges with a practical methodology.
Contact Information:
Kanishk
Page updated
Google Sites
Report abuse